Vertex and CRISPR Therapeutics Forge Deal on Gene Editing for Rare Disease

October 26, 2015 | In the latest major partnership around gene editing therapies based on CRISPR-Cas9 technology, Vertex is investing $105 million upfront in CRISPR Therapeutics, to support programs in cystic fibrosis and sickle cell disease, among other conditions. Xconomy